Wednesday, November 4, 2009

Cancer Treatment Centers of America (CTCA)

Cancer Treatment Centers of America (CTCA) is a private operator of cancer treatment hospitals and outpatient clinics which provide both conventional and alternative medical treatments.. CTCA has four hospitals in the United States: Midwestern Regional Medical Center in Zion, Illinois, Southwestern Regional Medical Center in Tulsa, Oklahoma, Eastern Regional Medical Center in Philadelphia, and Western Regional Medical Center in Goodyear, Arizona. An outpatient oncology clinic, Seattle Cancer Treatment and Wellness Center, is located in Seattle, Washington.

CTCA was founded in 1988 by Richard J Stephenson after his mother lost her battle with cancer. Stephenson was unsatisfied with the treatment options available to his mother and opened the first CTCA hospital with the mission of changing the face of cancer
The first hospital to open was Midwestern Regional Medical Center in northern Illinois.

Traditional cancer treatments approved by the U.S. Food and Drug Administration (FDA) such as surgery, radiation, chemotherapy, and stem cell transplants are offered at CTCA . Nutritional support, naturopathic medicine, mind-body medicine, spiritual counseling, and other complementary and alternative therapies are also available. CTCA promotes a model of integrating traditional treatments with complementary therapies.

CTCA advertises itself as the home of integrative and compassionate cancer care under the motto: "We never stop searching for and providing powerful and innovative therapies to heal the whole person, improve quality of life and restore hope

Cancer Treatment Centers of America was the subject of a Federal Trade Commission (FTC) complaint in 1993. The FTC alleged that CTCA made false claims regarding the success rates of certain cancer treatments in their promotional materials. This claim was settled in March 1996, requiring CTCA to discontinue use of any unsubstantiated claims in their advertising. CTCA is also required to have proven, scientific evidence for all statements regarding the safety, success rates, endorsements, and benefits of their cancer treatments. CTCA was also required to follow various steps in order to report compliance to the FTC per the settlement.

source :
picture source :


Sunday, November 1, 2009


Thyroid neoplasm or thyroid cancer usually refers to any of four kinds of malignant tumors of the thyroid gland: papillary, follicular, medullary or anaplastic. Most patients are 25 to 65 years of age when first diagnosed; women are more affected than men. Papillary and follicular tumors are the most common. They grow slowly and may recur, but are generally not fatal in patients under 45 years of age. Medullary tumors have a good prognosis if restricted to the thyroid gland and a poorer prognosis if metastasis occurs. Anaplastic tumors are fast-growing and respond poorly to therapy.

Thyroid nodules are diagnosed by ultrasound guided fine needle aspiration (USG/FNA) or frequently by thyroidectomy (surgical removal and subsequent histological examination). As thyroid cancer can take up iodine, radioactive iodine is commonly used to treat thyroid carcinomas, followed by TSH suppression by high-dose thyroxine therapy.

After a nodule is found during a physical examination, a referral to an endocrinologist, a thyroidologist or otolaryngologist may occur. Most commonly an ultrasound is performed to confirm the presence of a nodule, and assess the status of the whole gland. Measurement of thyroid stimulating hormone and anti-thyroid antibodies will help decide if there is a functional thyroid disease such as Hashimoto's thyroiditis present, a known cause of a benign nodular goiter.

Fine needle biopsy

One approach used to determine whether the nodule is malignant is the fine needle biopsy (FNB), which some have described as the most cost-effective, sensitive and accurate test.

FNB or ultrasound-guided FNA usually yields sufficient thyroid cells to assess the risk of malignancy, although in some cases, the suspected nodule may need to be removed surgically for pathological examination.

Rarely, a biopsy is done using a large cutting needle, so that a piece of nodule capsule can be obtained.

Blood tests

Blood or imaging tests may be done prior to or in lieu of a biopsy. The possibility of a nodule which secretes thyroid hormone (which is less likely to be cancer) or hypothyroidism is investigated by measuring thyroid stimulating hormone (TSH), and the thyroid hormones thyroxine (T4) and triiodothyronine (T3).

Tests for serum thyroid autoantibodies are sometimes done as these may indicate autoimmune thyroid disease (which can mimic nodular disease).


The blood assays may be accompanied by ultrasound imaging of the nodule to determine the position, size and texture, and to assess whether the nodule may be cystic (fluid filled). Also suspicious findings in a nodule are hypoechoic, irregular borders, microcalcifications, or very high levels of blood flow within the nodule. Less suspicious findings in benign nodules include, hyperechoic, comet tail artifacts from colloid[clarification needed], no blood flow in the nodule and a halo, or smooth border.

Some clinicians will also request technetium (Tc) or radioactive iodine imaging of the thyroid. An 123I scan showing a hot nodule, accompanied by a lower than normal TSH, is strong evidence that the nodule is not cancerous.

Related Posts with Thumbnails

  © All Cancer Article and Healthy Spain by 2008

Back to TOP